Olaparib is recommended as maintenance therapy for ovarian cancer patients with germline BRCA mutations who responded favorably to chemotherapy treatments46 and for prostate cancer patients with BRCA or ATM mutations47. This evidence concerns the gene ATM and prostate carcinoma.